Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Lessened by Prudential Financial Inc.

Prudential Financial Inc. trimmed its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 77.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,753 shares of the biopharmaceutical company’s stock after selling 64,212 shares during the quarter. Prudential Financial Inc.’s holdings in Alnylam Pharmaceuticals were worth $4,413,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in ALNY. Allworth Financial LP grew its stake in Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 38 shares in the last quarter. Nixon Peabody Trust Co. grew its position in shares of Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after acquiring an additional 43 shares in the last quarter. IFP Advisors Inc grew its position in shares of Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 47 shares in the last quarter. Nwam LLC increased its holdings in shares of Alnylam Pharmaceuticals by 5.8% in the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock valued at $213,000 after acquiring an additional 50 shares during the last quarter. Finally, SYM FINANCIAL Corp raised its position in shares of Alnylam Pharmaceuticals by 6.2% during the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 55 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $270.02 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The stock has a market capitalization of $35.13 billion, a P/E ratio of -124.43 and a beta of 0.39. The firm’s 50 day moving average is $260.34 and its 200-day moving average is $260.58. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock valued at $19,958,097 over the last three months. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $353.00 target price for the company. Scotiabank increased their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a research note on Monday. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $280.00 to $328.00 in a research note on Monday, March 24th. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Finally, Chardan Capital restated a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $316.25.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.